Castration Resistant Prostate Cancer Therapeutics
1. Erleada patent expiration
Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Improvement of overall survival and progression free survival in metastatic, castration-resistant prostate cancer (mcrpc) patients...
ERLEADA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8445507 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Sep, 2030
(4 years from now) | |
| US9481663 | JANSSEN BIOTECH | Crystalline forms of an androgen receptor modulator |
Jun, 2033
(7 years from now) | |
| US9388159 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802689 | JANSSEN BIOTECH | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
Mar, 2027
(1 year, 2 months from now) | |
| US12303497 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(14 years from now) | |
| US10052314 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| USRE49353 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US10849888 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US10702508 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Apr, 2038
(12 years from now) | |
| US9884054 | JANSSEN BIOTECH | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
Sep, 2033
(7 years from now) | |
| US11963952 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(14 years from now) | |
| US9987261 | JANSSEN BIOTECH | Substituted diazaspiroalkanes as androgen receptor modulators |
Mar, 2027
(1 year, 2 months from now) | |
| US12303493 | JANSSEN BIOTECH | Anticancer compositions |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
2. Lynparza patent expiration
Treatment: Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy...
LYNPARZA's oppositions filed in EPO
LYNPARZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7151102 | ASTRAZENECA | Phthalazinone derivatives |
Apr, 2022
(3 years ago) | |
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(1 year, 2 months ago) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Sep, 2027
(1 year, 7 months from now) | |
| US8247416 | ASTRAZENECA | Phthalazinone derivative |
Sep, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US8912187 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US11970530 | ASTRAZENECA | Methods of treating homologous recombination deficient cancer |
Oct, 2041
(15 years from now) | |
| US9566276 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(5 years from now) | |
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US9169235 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US11975001 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US11633396 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US8475842 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Dec, 2029
(3 years from now) | |
| US12048695 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US12178816 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US12144810 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Dosage: TABLET; CAPSULE
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
3. Nubeqa patent
expiration
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer; Treatment of adult patients with metastatic castration-sensi...
NUBEQA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Mar, 2033
(7 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(4 years from now) | |
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(4 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(12 years from now) | |
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329742 | BAYER HEALTHCARE | Pharmaceutical composition of darolutamide |
May, 2042
(16 years from now) | |
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
| New Indication(I-971) | Jun 03, 2028 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Dosage: TABLET
More Information on Dosage
NUBEQA family patents
4. Vanrafia patent expiration
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121509 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US11998526 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US11874283 | NOVARTIS | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
Feb, 2032
(6 years from now) | |
| US11491137 | NOVARTIS | Methods of improving renal function |
Dec, 2040
(14 years from now) | |
| US9364458 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(8 years from now) | |
| US8623819 | NOVARTIS | Therapy for complications of diabetes |
Aug, 2028
(2 years from now) | |
| US12370174 | NOVARTIS | NA |
Dec, 2040
(14 years from now) | |
| US10016393 | NOVARTIS | Stabilized pharmaceutical dosage forms comprising atrasentan |
Jul, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents
5. Xtandi patent expiration
Treatment: Treatment of patients with metastatic castration-resistant prostate cancer to whom rifampin is administered with the co-administration of a daily dose of 240 mg enzalutamide; Treatment of patients wit...
XTANDI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7709517 | ASTELLAS | Diarylhydantoin compounds |
Aug, 2027
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12161628 | ASTELLAS | Combination therapy |
Feb, 2037
(11 years from now) | |
| US12447128 | ASTELLAS | NA |
Sep, 2033
(7 years from now) | |
| US11839689 | ASTELLAS | Formulations of enzalutamide |
Sep, 2033
(7 years from now) | |
| US8183274 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
Aug, 2026
(7 months from now) | |
| US9126941 | ASTELLAS | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
May, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 31, 2017 |
| New Indication(I-693) | Sep 10, 2017 |
| New Indication(I-786) | Jul 13, 2021 |
| New Indication(I-808) | Dec 16, 2022 |
| New Indication(I-926) | Nov 17, 2026 |
Drugs and Companies using ENZALUTAMIDE ingredient
Market Authorisation Date: 04 August, 2020
Dosage: CAPSULE; TABLET
How can I launch a generic of XTANDI before it's drug patent expiration?
More Information on Dosage
XTANDI family patents
6. Zytiga patent expiration
Treatment: Use in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer; Use in combination with prednisone for the treatment of patients with m...
ZYTIGA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822438 | JANSSEN BIOTECH | Methods and compositions for treating cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US5604213 | JANSSEN BIOTECH | 17-substituted steroids useful in cancer treatment |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-663) | Dec 10, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2016 |
| New Indication(I-765) | Feb 07, 2021 |
Drugs and Companies using ABIRATERONE ACETATE ingredient
NCE-1 date: 29 April, 2015
Market Authorisation Date: 28 April, 2011
Dosage: TABLET
How can I launch a generic of ZYTIGA before it's drug patent expiration?
More Information on Dosage
ZYTIGA family patents